drugset / Trial / NCT00158743

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

NCT00158743 ↗

Phase 2 Completed 51 enrolled BTG International Inc. GlaxoSmithKline · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether a commercially available anti-digoxin antibody, Digibind, can delay delivery in patients with severe pre-eclampsia. If so, this would allow more time for maternally administered steroids to prevent the development of respiratory complications in premature infants.

Timeline

Start
2004-02
Primary completion
2007-12
Completion
2007-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Digibind Protein / enzyme biologic — Intravenous

Indications